The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Abstract
Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population.Methods We did a global, phase 3, randomised, open-label trial at 76 sites in 14 countries. Eligible patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy were randomly assigned (1:1) using an interactive web response system at a central location to receive either nanoliposomal irinotecan monotherapy (120 mg/m(2) every 3 weeks, equivalent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid. A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1:1:1), in a protocol amendment. Randomisation was stratified by baseline albumin, Karnofsky performance status, and ethnic origin. Treatment was continued until disease progression or intolerable toxic effects. The primary endpoint was overall survival, assessed in the intention-to-treat population. The primary analysis was planned after 305 events. Safety was assessed in all patients who had received study drug. This trial is registered at ClinicalTrials.gov, number NCT01494506.Findings Between Jan 11, 2012, and Sept 11, 2013, 417 patients were randomly assigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or fluorouracil and folinic acid (n=149). After 313 events, median overall survival in patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8-8.9) vs 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI 0.49-0.92; p=0.012). Median overall survival did not differ between patients assigned nanoliposomal irinotecan monotherapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4.2 months [3.6-4.9]; 0.99, 0.77-1.28; p=0.94). The grade 3 or 4 adverse events that occurred most frequently in the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]).Interpretation Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy. This agent represents a new treatment option for this population.Funding Merrimack Pharmaceuticals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients progressing on first-line regimens can be offered the possibility of switching to the other regimen, or a second-line regimen that includes a liposomal formulation of irinotecan in combination with 5-FU10, provided they have not received either of these agents previously.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [10]
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationBurris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Oettle, H., Riess, H. B., Stieler, J., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 492
Self-citationKalra, A. V., Kim, J., Klinz, S. G., Paz, N., Cain, J. E., Drummond, D. C., Nielsen, U. B., & Fitzgerald, J. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0572 · Cited by 199
Self-citationPharmacogenetics of irinotecan metabolism and transport: An update
Smith, N. F., Figg, W. D., & Sparreboom, A. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.045 · Cited by 190
Yoo, C., Hwang, J. Y., Kim, J. H., Kim, T. W., Lee, J. S., Park, D. H., Lee, S. K., Seo, D. W., Lee, S. S., Kim, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605374 · Cited by 169
Self-citationKo, A. H., Tempero, M. A., Shan, Y.-S., Su, W., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Self-citationRoy, A. C., Park, S. R., Cunningham, D., Kang, Y., Chao, Y., Chen, L., Rees, C., Lim, H. Y., Tabernero, J. M., Ramos, F. J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt002 · Cited by 123
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,000
Wong, S. K., Gondara, L., Renouf, D. J., Lim, H. J., Loree, J. M., Davies, J. M., & Gill, S. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-422 · Cited by 2
“In the palliative setting, newer treatment options have led to improvements in median overall survival (16,17,21,22) and patient-reported quality of life (23,24).”
New drugs and options can enhance patient outcomes: But can they also erode them?
Kim, M. S., & Prasad, V. K. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.047 · Cited by 3
Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma
Kamgar, M., Chakrabarti, S., Shreenivas, A. V., & George, B. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.06.004 · Cited by 3
To, Y. H., Shapiro, J., Wong, R., Thomson, B. N. J., Nagrial, A. M., Mendis, S. R., Gibbs, P., Shapiro, J. D., & Lee, B. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13721 · Cited by 3
Hino, K., Nishina, T., Numata, Y., Asagi, A., Inoue, T., Yoshimatsu, M., Sakaguchi, C., Nakasya, A., Nishide, N., Kajiwara, T., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8736-21 · Cited by 3
“No standard regimen for second-line chemotherapy was established until recently, when the survival benefit of nanoliposomal irinotecan plus 5-FU/leucovorin (nal-IFL) over 5-FU/leucovorin alone was demonstrated (7).”
BackgroundInfluentialJiang, T., Gao, C., Luo, Y., Ye, Z., & Wang, B. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s369772 · Cited by 3
“1 months.(18) Considering that the patient had a good performance status (PS=0) with PD-L1(20%+) and was willing to fight for a prolonged survival, we initiated him the FOLFIRINOX plus Toripalimab.”
BackgroundChiang, N., Shan, Y., Li, C., Yang, S., Su, Y., Chiu, S.-C., Bai, L., Chuang, S., Chan, D., Yen, C., et al. (2022) · PubMed Central · Cited by 3
Self-citationSütçüoğlu, O., Doğan, A., Yılmaz, F., Şahin, A. B., Şahin, T. K., Esen, S. A., Erol, C., Üner, A., Özet, A., Turan, N., et al. (2023) · Pancreas · doi:10.1097/mpa.0000000000002238 · Cited by 3
Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials
Merz, V., Messina, C. G. M., Zecchetto, C., Quinzii, A., Frisinghelli, M., Trentin, C., Salati, M., Caffo, O., & Melisi, D. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.12.005 · Cited by 3
Uehara, M., Domoto, T., Takenaka, S., Takeuchi, O., Shimasaki, T., Miyashita, T., & Minamoto, T. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.84 · Cited by 3
Liu, Y., Guo, X., Xu, P., Song, Y., Huang, J., Chen, X., Zhu, W., Hao, J., & Gao, S. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0036 · Cited by 2
“This finding was notably superior to the median OS of 4.2 months achieved with a 5-FU and LV combination (HR = 0.67, 95% CI = 0.49–0.92; P = 0.012) 32 .”
ResultInfluentialLiposomal Technology in Drug Formulations: Enhancing Therapeutic Efficacy and Safety
Patel, V., & Dave, P. Y. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1007868 · Cited by 3
The Role of Nanoparticles in Therapy of Real-World Patients with Pancreatic Cancer: A Scoping Review
Konstantinidis, I. K., Tsokkou, S., Katsikeros, D., Chatzikomnitsa, P., Papakonstantinou, M., Liampou, E., Toutziari, E., Giakoustidis, D. E., Bangeas, P., Papadopoulos, V. N., et al. (2025) · Cancers · doi:10.3390/cancers17101726 · Cited by 3
Itoh, A., Shibuya, K., Kimura, N., Fukasawa, M., Kawai, S., Igarashi, T., Watanabe, T., Hirano, K., Yoshioka, I., & Fujii, T. (2025) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-025-02175-2 · Cited by 3
Egger, J., Schmalstieg, D., Bettac, L., Hanle, M., Hann, A., Chen, X., Grater, T., Egger, J., Zoller, W. G., & Hann, A. (2017) · Biomedical Engineering International Conference · doi:10.1109/bmeicon.2017.8229099 · Cited by 3
Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management
Akce, M., & El‐Rayes, B. F. (2019) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2019.15.1.27 · Cited by 3
Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials
Kaur, J., Singh, P., Enzler, T., & Sahai, V. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1905795 · Cited by 3
“1 months, respectively, and based on these data; the combination arm received Food and drug administration (FDA) approval [7].”
BackgroundNanoliposomal irinotecan for treating pancreatic cancer
Grapsa, D., Syrigos, K., & Saif, M. W. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1169171 · Cited by 3
“To the best of our knowledge, previous data on the clinical use of MM-398 as an anticancer agent in advanced-stage solid tumors are limited to four clinical trials,[17,47,54,55] including two pancreatic cancer trials (phase II and III, respectively).”
BackgroundMethodInfluentialOstwal, V. S., Ramaswamy, A., Parthiban, S. K., Malhotra, M., Kothari, R. K., Goel, A., BHARGAVA, P. G., Srinivas, S., & Kulkarni, S. S. (2018) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_553_17 · Cited by 3
Dog-specific hemorrhagic changes induced by liposomal formulations, in the liver and the gallbladder
Makita-Suzuki, K., Kakinuma, C., Inomata, A., Shimada, Y., Hara, T., & Yao, T. (2019) · Journal of Toxicologic Pathology · doi:10.1293/tox.2019-0029 · Cited by 3
Xie, N., Hu, X., Tang, Y., Tian, C., He, Y., Hu, Z.-Y., Hu, C., Wang, X., Liu, X., Liu, L., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054135 · Cited by 3
Stromal Barriers Within the Tumor Microenvironment and Obstacles to Nanomedicine
Tanaka, H. Y., & Kano, M. R. (2019) · Springer eBooks · doi:10.1007/978-4-431-56880-3_4 · Cited by 3
Fanale, D., Madonia, G., Galvano, A., Peeters, M., ten Tije, A. J., Iovanna, J., & Russo, A. D. (2021) · UNIPA Springer series · doi:10.1007/978-3-030-56051-5_40 · Cited by 3
2016: advances in medical oncology
Chubenko, V. A. (2017) · Practical oncology · doi:10.31917/1801115 · Cited by 3
Neoplasms of the Exocrine Pancreas
Wolff, R. A., Li, D., Maitra, A., Tsai, S., Koay, E. J., & Evans, D. B. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm094.pub2 · Cited by 3
Palliative Chemotherapy for Advanced Pancreatic Cancer
Springfeld, C., & Seufferlein, T. T. W. (2023) · doi:10.1002/9781119876007.ch153 · Cited by 3
Self-citationWalker, E. J., Ko, A. H., & Tempero, M. A. (2023) · doi:10.1002/9781119823766.ch25 · Cited by 3
Medikamentöse Therapie des Pankreaskarzinoms
Feldmann, G. (2020) · Der Internist · doi:10.1007/s00108-020-00750-y · Cited by 2
Kraj, L., Chmiel, P., Śliwczyński, A. M., Szymański, Ł., Woźniak, K., Słodkowski, M., Stokłosa, T., & Wyrwicz, L. S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05962-5 · Cited by 2
Kabir, E. R., Azam, F., Khan, T. T. S., Yasmin, H., Chowdhury, N. M., Ahmed, S. M., Sagar, B. H., & Tahrim, N. A. (2024) · Cancer Medicine · doi:10.1002/cam4.70289 · Cited by 2
Araki, T., Kawahira, M., Shimokawa, M., Otsuka, T., Hayashi, K., Sonoda, Y., Honda, T., Nakao, K., Shibuki, T., Nakazawa, J., et al. (2024) · Oncology · doi:10.1159/000542137 · Cited by 2
Hung, Y.-S., Chiu, T., Chen, Y.-Y., & Chou, W. (2025) · Cancer Control · doi:10.1177/10732748251333040 · Cited by 2
Self-citationJain, A., Goel, V., Soni, S., Patnaik, N., Jaju, A., Goel, S., Basu, D. A., Talwar, V., & Singh, S. (2025) · Cureus · doi:10.7759/cureus.87389 · Cited by 2
“GN, on the other hand, led to more non-hematologic toxicities, such as gastrointestinal side effects and neuropathy, consistent with findings from the MPACT trial and other global studies [2,7,9].”
Al‐Sulaiti, F. K., & Şahin, S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107252 · Cited by 2
Giuliani, J., Mangiola, D., Napoli, G., Muraro, S., Tommasi, M., Fiorica, F., & Sava, T. (2025) · Pancreatology · doi:10.1016/j.pan.2025.08.007 · Cited by 2
Adams, J. P., Pauli, L., Wang, L., Valerio, T. I., Furrer, C. L., Li, M., Takebe, N., Tuohy, J. L., & Chen, W. R. (2025) · APL Bioengineering · doi:10.1063/5.0252574 · Cited by 2
Ge, Z., Zhang, Q., Wang, Y., Miao, L., Wang, X., Fan, N., Duan, L., Li, Y., & Qi, X. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03951-y · Cited by 2
“Despite advantages, Onivyde’s black box warning for severe diarrhea and neutropenia likely stems from carrier instability under physiological conditions, including interactions with plasma proteins, and circulatory shear forces [30].”
Kranjc, M., Cankar, U., & Novak, T. (2024) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/mfl0ydhabz · Cited by 2
Borrego, M. R., Páez, D., Vila, M. M., Pérez-García, J. M., Fernández-Abad, M., Tormo, S. B., García-Sáenz, J. Á., Lema, L., Garau, I., Cortez, P., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116161 · Cited by 2
Schram, A. M., Yang, S., Kahn, G., Velasco, R., Repetto, M., Gian, R. K., DiNapoli, S. E., Sukhadia, P., Troxel, M., Özcan, K., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf361 · Cited by 2
Kitagawa, K., Asada, S., Hanatani, J., Motokawa, Y., Osaki, Y., Iwata, T., Mitoro, A., & Yoshiji, H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041410 · Cited by 2
Zhang, X., Ye, X., Ding, Y., Du, Q., Wang, M., & Liu, J. (2026) · Nanotoxicology · doi:10.1080/17435390.2026.2629809 · Cited by 2
“…trials and prior studies have documented adverse events including gastrointestinal and hematologic toxicities, which—though manageable in controlled trial settings—manifest with greater severity in real-world clinical practice (Ettrich et al. 2024; Vogel et al. 2024; Wang-Gillam et al. 2016).”
Ning, W., Liu, H., Zeng, H., Qin, X., Xu, L., Yang, S., Wang, Y., Chen, F., Yuan, N., Chen, X., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102688 · Cited by 2
Self-citationZhang, X., Tao, X., Zhang, Y., Gan, G., Lv, J., Zhang, L., & Dong, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1785625 · Cited by 3
Wang, D. K., Steele, J. A., Opalenik, S. R., & Balko, J. M. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-07964-y · Cited by 2
Kawaguchi, Y., Hayashi, K., Shimokawa, M., Otsuka, T., Nakazawa, J., Shimokawa, H., Shinohara, Y., Koga, F., Oza, N., Oda, H., et al. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261442386 · Cited by 2
Takrori, E., Abdulmajid, M., Devagudi, D., Sohail, R., Sadiq, Z., Berneau, C., Shenouda, A., Adelli, R., Peshin, S., & Singal, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104413 · Cited by 2
Nanoparticle-Enabled Biomaterials for Controlled Drug Delivery in Implantable and Wearable Devices
Asiri, Z., Mobarki, A., Alghamdi, S. S., Almoutairi, A. A., Alsalman, F., Fitaihi, R. A., Altuwaijri, N., Alsubait, A., & Jamous, Y. F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167265 · Cited by 3
Ko, A. H. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000294 · Cited by 2
Administration sequence for multi-agent oncolytic regimens
Morales, A. S. R., Joy, J. K., & Zbona, D. M. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219895070 · Cited by 2
Gutiérrez-Sainz, L., Viñal, D., Villamayor, J., Martínez-Pérez, D., Garcia-Cuesta, J. A., Ghanem, I., Custodio, A., & Feliú, J. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02589-7 · Cited by 2
Kim, S.-R., Lee, H. J., & Kim, D. (2021) · Case Reports in Oncology · doi:10.1159/000521315 · Cited by 2
Striefler, J. K., Stieler, J., Neumann, C., Geisel, D., Ghadjar, P., Sinn, M., Malinka, T., Pratschke, J., Stintzing, S., Oettle, H., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164905 · Cited by 2
Self-citationManagement of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation
Liu, T., Cheng, S., Xu, Q., & Wang, Z. P. (2022) · Medicina · doi:10.3390/medicina58091298 · Cited by 2
Militello, A. M., Orsi, G., Cavaliere, A., Niger, M., Avallone, A., Salvatore, L., Tortora, G., Rapposelli, I. G., Giordano, G., Noventa, S., et al. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04585-w · Cited by 2
Systemic therapy for metastatic pancreatic cancer
Chikhareva, Y., Fedyanin, M. Y., Bazin, I. S., Покатаев, И. А., & Tryakin, A. A. (2023) · Malignant tumours · doi:10.18027/2224-5057-2023-13-4-60-68 · Cited by 2
Marinova, M., Khouri, D.-A., Küppers, J., Ramig, O., Strunk, H. M., Breuers, J., Fazaal, J., Fuhrmann, C., Coenen, M., Möhring, C., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133717 · Cited by 2
Akagi, T., Hamano, H., Miyamoto, H., Takeda, T., Zamami, Y., & Ohyama, K. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03767-6 · Cited by 2
“Recently, a liposomal formulation of irinotecan was developed and shown to be effective [16].”
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3
Wainberg, Z. A., & O'Reilly, E. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00952-5 · Cited by 2
Macarulla, T. M., Martín, A. J. M., de Castro, E. M., Trujillo, O. A. C., Cano, M. T., Castet, F., Tocino, R. V., Arias, A. F., Ghanem, I., Díaz, I. A., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100116 · Cited by 2
Self-citationLong, R., Guo, H., & Chen, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-90960-x · Cited by 2
Liu, N., Tu, Y., Wang, H., Zheng, X., Ji, F., Geng, M., Wei, X. P., Xin, J., He, W., Zhao, Q., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101309 · Cited by 2
Current perspectives and future strategies of chemotherapy for pancreatic cancer: a narrative review
Chon, H. J. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0061 · Cited by 2
Wang, Q., Lv, N., Xu, D., Wu, Y. F., Wu, J., Gao, W., Wei, J., Xiao, B., Tu, M., & Jiang, K. (2025) · BMC Cancer · doi:10.1186/s12885-025-14601-2 · Cited by 2
“Another RCT study, NAPOLI-1 which made a splash, suggested that nano-liposomal irinotecan in combination with fluorouracil and folinic acid as second-line therapy extends survival in patients with metastatic pancreatic cancer previously treated with gemcitabine-based regimens [11].”
InfluentialMiwa, K., Kawasaki, R., Shimokawa, M., Otsuka, T., Tanaka, T., Fukahori, M., Shibuki, T., Nakazawa, J., Arima, S., Koga, F., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1626689 · Cited by 2
Developing Effective Salmonella-based Approaches to Treat Pancreatic Cancer
Chen, J., & Diamond, D. J. (2016) · Pancreatic Disorders and Therapy · doi:10.4172/2165-7092.1000167 · Cited by 2
Self-citationPrecision Therapy of Pancreatic Cancer: From Bench to Bedside
Ciecielski, K. J., Berninger, A., & Algül, H. (2020) · Visceral Medicine · doi:10.1159/000509232 · Cited by 2
Vijayvergia, N., & Cohen, S. J. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.01 · Cited by 2
“MM-398 alone did not improve outcome compared to 5-FU (55).”
BackgroundNovel Therapeutic Modalities for Metastatic Pancreatic Cancer
Bang, S. (2016) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2016.21.4.185 · Cited by 2
“012).(17) Gemcitabine을 기반으로 하는 초치료에 실패한 진행성 췌장”
Up to date of chemotherapy for pancreatic cancer.
Furuse, J. (2017) · PubMed · doi:10.11405/nisshoshi.114.637 · Cited by 2
Ramanathan, R. K., Weiss, G. J., Posner, R. G., Rajeshkumar, N. V., Jameson, G., Aziz, M., Hoering, A., Bolejack, V., Maitra, A., Fulk, M., et al. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.09.05 · Cited by 2
Self-citationOvercoming diagnostic issues in precision treatment of pancreatic cancer
Löhr, M. J., Kordes, M., Rutkowski, W., Heuchel, R. L., Gustafsson‐Liljefors, M., Russom, A., & Nilsson, M. F. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1476061 · Cited by 2
Stellenwert der Metastasenchirurgie beim fortgeschrittenen Pankreaskarzinom
Bruns, C. J., Gebauer, F., Scheufele, F., & Friess, H. (2019) · Der Onkologe · doi:10.1007/s00761-019-0547-8 · Cited by 2
Management of ductal pancreatic cancer
Djanani, A. M., Schmiderer, A., Niederreiter, L., Niederreiter, M., & Tilg, H. (2019) · European surgery. Supplement/European surgery · doi:10.1007/s10353-019-0583-z · Cited by 2
Latest developments in chemotherapy for metastatic pancreatic cancer
Khan, A. K., Jain, A. G., Afridi, S., Wazir, M., Rao, J. S., & Ahmad, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819457-7.00006-2 · Cited by 2
Guo, X., Xu, Y., Ji, Y., Fan, Y., Wang, D., Jin, D., Zhuang, R., Wu, L., Lou, W., & Zhou, Y. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000038 · Cited by 2
Saif, M. W. (2020) · PubMed · Cited by 2
A New Targeted Treatment for Patients with a Germline BRCA Mutation: Olaparib in Pancreatic Cancer
Verdaguer, H., Acosta, D., & Macarulla, T. M. (2020) · Future Oncology · doi:10.2217/fon-2020-0334 · Cited by 2
Self-citationCurrent Systemic Treatment Options for Metastatic and Unresectable Pancreatic Cancer
Caglevic, C., Mauricio Mahave, C., Sanhueza, C. T., & Ubillos, L. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.93225 · Cited by 2
Motoi, F. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.75 · Cited by 2
Recomendaciones para el diagnóstico y tratamiento del adenocarcinoma ductal de páncreas
Pasqua, A. V., Moro, M., Alle, L., Basso, S., Canicoba, M., Capitanich, P., Carballido, M., Cayol, F., Crisci, J., Fernández, D., et al. (2020) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/xaqm8690 · Cited by 2
Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials
Kang, B. W., & Chau, I. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1995354 · Cited by 2
Spectacular Progress in Lung Cancer Care
(2021) · ONCOLOGY · doi:10.46883/onc.2021.3501.0026 · Cited by 2
Chemotherapy for Advanced Pancreatic Cancer
Sclafani, F., Cunningham, D., Okines, A. F. C., Ratnayake, G., & Chau, I. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_37 · Cited by 2
Self-citationCase 19-2022: A 29-Year-Old Woman with Jaundice and Chronic Diarrhea
Dubois, J. S., Kambadakone, A. R., Wo, J. Y.-L., & Zhang, M. L. (2022) · New England Journal of Medicine · doi:10.1056/nejmcpc2201231 · Cited by 2
Nanovesicles for intravenous drug delivery
Gülteki̇n, H. E., Öner, E., İlhan, M., & Karpuz, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91865-7.00018-3 · Cited by 2
Advanced pancreatic cancer: diagnosis and systemic treatment evolution over the last decades
Raczyński, I., Didkowska, J. A., & Radecka, B. S. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2022.0030 · Cited by 2
Hegewisch‐Becker, S., Kratz‐Albers, K., Wierecky, J., Gerhardt, S., Reschke, D. J., Borchardt, J., Reichelt, R., & Friedrich, F. W. (2022) · Future Oncology · doi:10.2217/fon-2022-0141 · Cited by 2
Chiang, C., Chiang, C., Chiang, C., Chiu, J.-H., Sheng‐Kai, K., Chen, B. S., Luan, Y., Cheng, T.-C., Hsieh, C.-L., & Peng, C. (2022) · Pancreas · doi:10.1097/mpa.0000000000002125 · Cited by 2
Pancreatic Cancer: Nanoparticle Targeted Therapy Via Epidermal Growth Factor Receptor
Dwivedi, V., Sameem, S., Rahman, M., Pathak, P., & Verma, A. (2022) · Springer eBooks · doi:10.1007/978-981-19-5558-7_6 · Cited by 2
Leeneman, B., Xander, N., Fiets, W. E., de Jong, W. K., Uyl, N. E. M., Wymenga, A. N. M., Reyners, A. K. L., & Groot, C. A. U. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114002 · Cited by 2
Mehta, A., Hwang, W. L., & Weekes, C. D. (2020) · Annals of Pancreatic Cancer · doi:10.21037/apc-2020-pda-05 · Cited by 2
“Other early studies are evaluating the role of liposomal irinotecan, 5-FU, leucovorin and oxaliplatin (NAPOX), an approved second-line treatment for metastatic PDAC after progression on gemcitabine (16), in the first-line setting for metastatic PDAC (17).”
BackgroundAdvances in the Management of Pancreatic Adenocarcinoma
O'Reilly, E. M. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.5014 · Cited by 2
Lee‐Ying, R. M., Ahmed, O., Ahmed, S., Ahmed, S., Bathe, O. F., Brunet, B., Dawson, L. A., Davies, J. M., Gordon, V., Hebbard, P. C., et al. (2021) · Current Oncology · doi:10.3390/curroncol28050310 · Cited by 2
Self-citationBukhari, N., Abdalla, K., Ibnshamsa, F., Alselwi, W., Al-Shakir, S., & Alqahtani, M. S. (2021) · Cureus · doi:10.7759/cureus.18756 · Cited by 2
“Second-line nano-liposomal irinotecan and infusional 5-FU showed a survival advantage in patients who progressed on first-line gemcitabine-based treatments [13].”
BackgroundPancreatic Adenocarcinoma: An Evolving Yet Unimpressive Treatment Landscape
Bashir, B., & Mueller, A. C. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00620 · Cited by 2
Descriptive comparison of hospital formulary decisions with published oncology valuation methods
Lam, S. W., Siebenaller, C., Earl, M. A., Hill, B. T., Kalaycio, M. E., Rini, B. I., Carraway, H. E., Leonard, M. C., & Sekeres, M. A. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219877927 · Cited by 1
Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost?
Yıldırım, S., Erdoğan, A. P., Karateke, M., Yılmaz, C., Özveren, A., Bulut, G., Ekinci, F., & Almuradova, E. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-020-00573-y · Cited by 1
Cui, J., Yang, H., Liu, J., Chen, D., Hu, J., Zhang, H., Wang, Y., Han, T., Mao, T., Jiao, F., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08375-6 · Cited by 1
“2months) in NAPOLI-1 trial which was used for second lines therapy [26].”
BackgroundMethodInfluentialOutcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging
Rogers, J. E., Mizrahi, J. D., Nogueras‐González, G. M., Surana, R., Shroff, R. T., Wolff, R. A., Varadhachary, G. R., Javle, M. M., Overman, M. J., Raghav, K. P. S., et al. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-569 · Cited by 1
“Limited data shows a potential survival benefit with second-line therapy (6-8).”
BackgroundSelf-citation
Metadata
- Authors
- Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., Hubner, R. A., Chiu, C.-F., Schwartsmann, G., Siveke, J. T., Braiteh, F., Moyo, V., Belanger, B., Dhindsa, N., Bayever, E., Von Hoff, D. D., Chen, L.-T., Adoo, C., Anderson, T., Asselah, J., Azambuja, A., Bampton, C., Barrios, C. H., Bekaii-Saab, T., Bohuslav, M., Chang, D., Chen, J.-S., Chen, Y.-C., Choi, H. J., Chung, I. J., Chung, V., Csoszi, T., Cubillo, A., DeMarco, L., de Wit, M., Dragovich, T., Edenfield, W., Fein, L. E., Franke, F., Fuchs, M., Gonzales-Cruz, V., Gozza, A., Fernando, R. H., Iaffaioli, R., Jakesova, J., Kahan, Z., Karimi, M., Kim, J. S., Korbenfeld, E., Lang, I., Lee, F.-C., Lee, K.-D., Lipton, L., Ma, W. W., Mangel, L., Mena, R., Palmer, D., Pant, S., Park, J. O., Piacentini, P., Pelzer, U., Plazas, J. G., Prasad, C., Rau, K.-M., Raoul, J.-L., Richards, D., Ross, P., Schlittler, L., Smakal, M., Stahalova, V., Sternberg, C., Seufferlein, T., Tebbutt, N., Vinholes, J. J., Wadlow, R., Wenczl, M., & Wong, M.
- Affiliations
- Taipei Veterans General Hospital (TW)
- St John of God Subiaco Hospital (AU)
- National Cheng Kung University Hospital (TW)
- Translational Genomics Research Institute (US)
- Vall d'Hebron Institute of Oncology (ES)
- Seoul National University Hospital (KR)
- Royal Marsden Hospital (GB)
- Hôpital Saint-André (FR)
- The Christie NHS Foundation Trust (GB)
- China Medical University Hospital (TW)
- Hospital de Clínicas de Porto Alegre (BR)
- TUM Klinikum (DE)
- Comprehensive Cancer Centers of Nevada (US)
- Merrimack Pharmaceuticals (United States) (US)
- Kaohsiung Medical University (TW)
- Corresponding author
- Chen, Li-Tzong
- ORCID
- Li, Chung-Pin
- Dean, Andrew
- Shan, Yan-Shen
- Jameson, Gayle
- Macarulla, Teresa
- Lee, Kyung-Hun
- Cunningham, David
- Hubner, Richard A
- Schwartsmann, Gilberto
- Siveke, Jens T
- Braiteh, Fadi
- Moyo, Victor
- Belanger, Bruce
- Chen, Li-Tzong
- Asselah, Jamil
- Barrios, Carlos Henrique
- Chang, David
- Chen, Jen-Shi
- Chen, Yeu-Chin
- Choi, Hye Jin
- Chung, Vincent
- Cubillo, Antonio
- Dragovich, Tomislav
- Fein, Luis Enrique
- Fuchs, Martin
- Korbenfeld, Ernesto
- Lee, Fa-Chyi
- Lee, Kuan-Der
- Ma, Wen Wee
- Palmer, Daniel
- Pant, Shubham
- Park, Joon Oh
- Pelzer, Uwe
- Rau, Kun-Ming
- Raoul, Jean-Luc
- Richards, Donald
- Ross, Paul
- Stahalova, Vladimira
- Sternberg, Cora
- Seufferlein, Thomas
- Tebbutt, Niall
- Wadlow, Raymond
- Wong, Mark
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 387
- Issue
- 10018
- Pages
- 545-557
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2187917981
- Cited by
- 1,222
- References
- 29
- Citations by year
- 2026: 92 · 2025: 123 · 2024: 122 · 2023: 116 · 2022: 119 · 2021: 156 · 2020: 117 · 2019: 116 · 2018: 99 · 2017: 101 · 2016: 53
- FWCI
- 37.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- 5-fluorouracil, leucovorin, metastatic pancreatic ductal adenocarcinoma, gemcitabine-refractory disease, combination chemotherapy, overall survival, first-line therapy, NAPOLI-1 trial, albumin, Karnofsky performance status
- MeSH terms
- Irinotecan, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Diarrhea, Fatigue, Female, Fluorouracil, Humans, Liposomes, Male, Middle Aged, Neoplasm Metastasis, Neutropenia, Pancreatic Neoplasms, Vomiting, Treatment Outcome, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
